David Bredt sold $197k of RAPP
Chief Scientific Officer at Rapport Therapeutics, Inc.. 6,567 shares at an average of $30.05, traded Dec 31, 2025, filed Jan 5, 2026.
Score components
- +15RoleOfficer
- +12Trade size$197k at market
- 0Share of holdings soldSold 1.6% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -3.9%, 3m +17.7%, 6m +40.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-002470, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 31, 2025 | AGrant or award Common Stock | -18,000 | - | - | 410,642 | Jan 5, 2026 |
| Dec 31, 2025 | SOpen-market sale Common Stock | -6,567 | $30.05 | $197k | 404,075 | Jan 5, 2026 |
Related signals
Other insiders at Rapport Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 24Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $143k 4,522 shares | -1% | |
| 23Weak | Rapport Therapeutics, Inc. | Cheryl Gault Chief Operating Officer | $332k 10,000 shares | -7% | |
| 22Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $87k 2,210 shares | -0% | |
| 20Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $374k 8,210 shares | -2% | |
| 29Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $938k 18,921 shares | -4% | |
| 30Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $2.4M 51,499 shares | -10% | |
| 15Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $93k 2,210 shares | -0% | |
| 20Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $328k 8,210 shares | -1% | |
| 20Weak | Rapport Therapeutics, Inc. | Abraham Ceesay Chief Executive Officer | $327k 8,220 shares | -1% | |
| 13Weak | Rapport Therapeutics, Inc. | Third Rock Ventures V, L.P. owner | $744k 18,572 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.